Ken Griffin Infla Rx N.V. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Infla Rx N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 5,200 shares of IFRX stock, worth $8,216. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,200
Previous 12,900
59.69%
Holding current value
$8,216
Previous $19,000
52.63%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding IFRX
# of Institutions
35Shares Held
13.2MCall Options Held
5.2KPut Options Held
0-
Suvretta Capital Management, LLC New York, NY5.73MShares$9.06 Million0.42% of portfolio
-
683 Capital Management, LLC New York, NY2.07MShares$3.27 Million0.33% of portfolio
-
Eversept Partners, LP New York, NY1.57MShares$2.48 Million0.21% of portfolio
-
Morgan Stanley New York, NY828KShares$1.31 Million0.0% of portfolio
-
Ubs Oconnor LLC Chicago, IL722KShares$1.14 Million0.07% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $69.8M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...